Yin Yan, Dong Lei, Yin Dong
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e79-87. doi: 10.1111/j.1440-1746.2007.05142.x. Epub 2007 Oct 17.
The action of the corticotrophin releasing factor (CRF) receptor on the small intestinal motility has been rarely investigated. The present study aimed to determine the effects of urocortin 1 on small intestinal motility in rats and the CRF receptor subtypes and autonomic pathways mediating the effects.
Fasted or fed rats were used to investigate the effect of intravenous or intracerebroventricular urocortin 1 on duodenum and jejunum motility. NBI-27914 and astressin(2)-B (CRF receptor 1 and 2 antagonists, respectively), atropine (an M-receptor antagonist), phentolamine (an alpha-receptor antagonist), propranolol (a beta-receptor antagonist) and N(omega)-Nitro-L-arginine (a nitric oxide synthase [NOS] inhibitor) were applied to determine the involved CRF receptor subtypes and autonomic pathways.
In fasted rats, intravenous or intracerebroventricular injection of urocortin 1 disrupted duodenal and jejunal migrating myoelectric complex pattern, leading to an irregular spiking activity similar to the fed motility pattern. When urocortin 1 was given in the fed state, the fed motility pattern remained unchanged. In addition, urocortin 1 also inhibited small intestinal transit function. Astressin(2)-B injected intraperitoneally or intracerebroventricularly blocked urocortin 1-induced change, while NBI-27914 had no effect. The disruption of migrating myoelectric complex induced by urocortin 1 was abolished by atropine, but not affected by phentolamine, propranolol and N(omega)-Nitro-L-arginine.
Intravenous or intracerebroventricular injection of urocortin 1 acts, respectively, on peripheral and central CRF receptor 2 to disrupt the intestinal migrating myoelectric complex through an M-receptor-dependent mechanism, and such change has an inhibitory effect as proved by measuring the small intestinal transit function.
促肾上腺皮质激素释放因子(CRF)受体对小肠运动的作用鲜有研究。本研究旨在确定尿皮质素1对大鼠小肠运动的影响以及介导该作用的CRF受体亚型和自主神经通路。
采用禁食或进食的大鼠来研究静脉注射或脑室内注射尿皮质素1对十二指肠和空肠运动的影响。分别应用NBI-27914和抗促肾上腺皮质激素释放因子(2)-B(分别为CRF受体1和2拮抗剂)、阿托品(M受体拮抗剂)、酚妥拉明(α受体拮抗剂)、普萘洛尔(β受体拮抗剂)和N(ω)-硝基-L-精氨酸(一氧化氮合酶[NOS]抑制剂)来确定所涉及的CRF受体亚型和自主神经通路。
在禁食大鼠中,静脉注射或脑室内注射尿皮质素1会破坏十二指肠和空肠的移行性肌电复合波模式,导致出现类似于进食时运动模式的不规则尖峰活动。当在进食状态下给予尿皮质素1时,进食时的运动模式保持不变。此外,尿皮质素1还会抑制小肠转运功能。腹腔内或脑室内注射抗促肾上腺皮质激素释放因子(2)-B可阻断尿皮质素1诱导的变化,而NBI-27914则无作用。尿皮质素1诱导的移行性肌电复合波的破坏可被阿托品消除,但不受酚妥拉明、普萘洛尔和N(ω)-硝基-L-精氨酸的影响。
静脉注射或脑室内注射尿皮质素1分别作用于外周和中枢的CRF受体2,通过M受体依赖性机制破坏肠道移行性肌电复合波,并且通过测量小肠转运功能证明这种变化具有抑制作用。